Enhancing healthcare professionals’ confidence in ethical decision-making when caring for people with dementia: A qualitative evaluation of the CARE intervention

by Clinical Neuropsychologist | Thursday, March 13, 2025 | Dementia

Dementia, Ahead of Print. Aim(s):To evaluate the impact of the CARE intervention on healthcare professionals’ perceived confidence levels and understand the factors influencing confidence in ethical decision-making in dementia care.Design:Thematic analysis of...

Beliefs and attitudes of family caregivers of People with dementia toward advance care planning: A Q methodology study

by Clinical Neuropsychologist | Wednesday, March 12, 2025 | Dementia

Dementia, Ahead of Print. Background:Family caregivers’ perspectives for advance care planning (ACP) are critically important to reflect the end-of-life wishes of people with dementia. Culture can influence ACP practice and people’s perspectives toward it. Little is...

“It’s almost like not existing”: Adult children’s experiences of not being recognized and their perceptions of being forgotten by their parents with dementia

by Clinical Neuropsychologist | Wednesday, March 12, 2025 | Dementia

Dementia, Ahead of Print. Parents living with dementia sometimes do not recognize their adult child caregivers, who may then perceive they are forgotten. Yet, research on the experience of being unrecognized and perceived as forgotten by a parent with dementia is...

Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology

by Clinical Neuropsychologist | Friday, March 7, 2025 | Dementia

Abstract INTRODUCTION The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer’s disease (AD) pathology manifests in sensory association areas...

Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer’s disease

by Clinical Neuropsychologist | Thursday, March 6, 2025 | Dementia

Abstract INTRODUCTION Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer’s disease (AD) and amyloid pathology, representing a target for therapeutic strategies. METHODS Amyloid and small ubiquitin modifier 2 (SUMO2)...

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract Virtually all people with Down syndrome will develop Alzheimer disease pathology during their lifetime. As Alzheimer disease is the third leading cause of death and a significant factor in end-of-life complications for adults with Down syndrome, identifying...